We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is SNEX Stock Worth Buying After Its Sharp Run and Richer Valuation?
Read MoreHide Full Article
Key Takeaways
SNEX has delivered record results, broad segment strength, rising client activity and acquisition benefits.
StoneX shares are up 110.2% in six months and trade at a premium to its sub-industry and sector.
SNEX needs R.J. O'Brien synergies, margin stability and expense control to support its valuation.
StoneX Group Inc. (SNEX - Free Report) has delivered the kind of operating acceleration investors usually reward: record results, broad-based segment strength, rising client activity and expanding benefits from acquisitions.
The harder question is whether the stock still offers an attractive entry point after a sharp rerating. The answer is mixed. Momentum supports the bull case, but the valuation now requires cleaner execution.
SNEX Earnings Momentum Looks Hard to Ignore
StoneX’s fiscal second-quarter 2026 results were difficult to dismiss. Earnings per share were $2.07, up 120% year over year and above the Zacks Consensus Estimate of $1.60. Operating revenues rose 64% to $1.57 billion, also ahead of the consensus mark, while net operating revenues climbed 70% to $829.1 million. Net income surged 143% to $174.3 million.
StoneX Group Inc. Price, Consensus and EPS Surprise
The strength was not isolated. Listed derivatives volume rose 59% to 97.2 million contracts, and average client equity plus money market/FDIC sweep balances reached about $15.2 billion, up 91% year over year. Commercial, Institutional, Self-Directed/Retail and Payments all contributed to the quarter’s performance, giving the earnings beat better quality than a one-product spike.
StoneX Profitability Supports the Bull Case
Profitability remains the key reason investors have been willing to pay more for SNEX. The company’s trailing-12-month ROE was 19.8% through the fiscal second quarter, above the industry average of 5.63% and ahead of the company’s long-term target of 15%.
These returns point to efficient capital deployment, especially because the business continues to scale across derivatives, securities, physical commodities, payments and retail channels. When client volumes, balances and cross-segment activity are healthy, StoneX’s model can convert activity into commissions, spreads, fees and interest income.
Why SNEX Valuation Demands Better Execution
The valuation is the main reason not to chase the stock without discipline. SNEX shares are up 110.2% in the past six months and 130.9% over the trailing 12-month period. The stock trades at 21.35X forward 12-month earnings, compared with 10.17X for the Zacks sub-industry and 16.29X for the Zacks Finance sector.
Image Source: Zacks Investment Research
The premium also shows up in book value. As of June 16, 2026, SNEX traded at 5.49X trailing 12-month book value, close to its five-year high of 5.65X and far above its five-year median of 1.73X. That leaves less room for disappointment if trading activity cools, acquisition integration slows or expenses pressure margins.
On the other hand, CME Group (CME - Free Report) offers a useful market-structure comparison because it operates a major derivatives marketplace where clients trade futures, options, cash and OTC markets. Interactive Brokers Group (IBKR - Free Report) is also relevant because it provides online trade execution and clearing across more than 170 market destinations, making it another financial-services name tied to trading activity and market access.
At present, CME Group is trading at a 20.89X forward 12-month earnings, while Interactive Brokers is trading at a 35.50X forward 12-month earnings.
StoneX Needs Synergies and Margin Stability
The R.J. O’Brien integration is central to whether the valuation premium holds. Annualized synergies reached about $32 million at the end of the fiscal second quarter and are expected to move closer to $45 million by fiscal 2026, with the rest realized in fiscal 2027. Management continues to target $50 million in annualized synergies.
The opportunity is meaningful. U.S. FCM consolidation began in May 2026 and is expected to reduce friction, support cross-selling of StoneX OTC products to legacy R.J. O’Brien clients and improve operating leverage. Still, risks remain. Payments RPM has been declining since fiscal 2025, Securities RPM has been volatile, fixed compensation and other expenses are rising, and bad debts increased in the latest quarter.
How Zacks Signals Could Guide an SNEX Decision
Zacks data support the earnings-momentum case, but they do not remove valuation risk. The Zacks Consensus Estimate points to earnings of $6.00 per share for fiscal 2026 and $6.25 for fiscal 2027, up from $3.93 in fiscal 2025. SNEX has also beaten the Zacks Consensus Estimate in two of the trailing four quarters.
Image Source: Zacks Investment Research
For investors, that argues for a balanced stance. SNEX still has strong business momentum, above-industry ROE and credible acquisition benefits. Yet after a major rally and a richer valuation, the stock looks better suited for investors comfortable with execution risk than for those seeking a low-risk entry point.
View the Zacks #1 Rank List
Image: Bigstock
Is SNEX Stock Worth Buying After Its Sharp Run and Richer Valuation?
Key Takeaways
StoneX Group Inc. (SNEX - Free Report) has delivered the kind of operating acceleration investors usually reward: record results, broad-based segment strength, rising client activity and expanding benefits from acquisitions.
The harder question is whether the stock still offers an attractive entry point after a sharp rerating. The answer is mixed. Momentum supports the bull case, but the valuation now requires cleaner execution.
SNEX Earnings Momentum Looks Hard to Ignore
StoneX’s fiscal second-quarter 2026 results were difficult to dismiss. Earnings per share were $2.07, up 120% year over year and above the Zacks Consensus Estimate of $1.60. Operating revenues rose 64% to $1.57 billion, also ahead of the consensus mark, while net operating revenues climbed 70% to $829.1 million. Net income surged 143% to $174.3 million.
StoneX Group Inc. Price, Consensus and EPS Surprise
StoneX Group Inc. price-consensus-eps-surprise-chart | StoneX Group Inc. Quote
The strength was not isolated. Listed derivatives volume rose 59% to 97.2 million contracts, and average client equity plus money market/FDIC sweep balances reached about $15.2 billion, up 91% year over year. Commercial, Institutional, Self-Directed/Retail and Payments all contributed to the quarter’s performance, giving the earnings beat better quality than a one-product spike.
StoneX Profitability Supports the Bull Case
Profitability remains the key reason investors have been willing to pay more for SNEX. The company’s trailing-12-month ROE was 19.8% through the fiscal second quarter, above the industry average of 5.63% and ahead of the company’s long-term target of 15%.
These returns point to efficient capital deployment, especially because the business continues to scale across derivatives, securities, physical commodities, payments and retail channels. When client volumes, balances and cross-segment activity are healthy, StoneX’s model can convert activity into commissions, spreads, fees and interest income.
Why SNEX Valuation Demands Better Execution
The valuation is the main reason not to chase the stock without discipline. SNEX shares are up 110.2% in the past six months and 130.9% over the trailing 12-month period. The stock trades at 21.35X forward 12-month earnings, compared with 10.17X for the Zacks sub-industry and 16.29X for the Zacks Finance sector.
Image Source: Zacks Investment Research
The premium also shows up in book value. As of June 16, 2026, SNEX traded at 5.49X trailing 12-month book value, close to its five-year high of 5.65X and far above its five-year median of 1.73X. That leaves less room for disappointment if trading activity cools, acquisition integration slows or expenses pressure margins.
On the other hand, CME Group (CME - Free Report) offers a useful market-structure comparison because it operates a major derivatives marketplace where clients trade futures, options, cash and OTC markets. Interactive Brokers Group (IBKR - Free Report) is also relevant because it provides online trade execution and clearing across more than 170 market destinations, making it another financial-services name tied to trading activity and market access.
At present, CME Group is trading at a 20.89X forward 12-month earnings, while Interactive Brokers is trading at a 35.50X forward 12-month earnings.
StoneX Needs Synergies and Margin Stability
The R.J. O’Brien integration is central to whether the valuation premium holds. Annualized synergies reached about $32 million at the end of the fiscal second quarter and are expected to move closer to $45 million by fiscal 2026, with the rest realized in fiscal 2027. Management continues to target $50 million in annualized synergies.
The opportunity is meaningful. U.S. FCM consolidation began in May 2026 and is expected to reduce friction, support cross-selling of StoneX OTC products to legacy R.J. O’Brien clients and improve operating leverage. Still, risks remain. Payments RPM has been declining since fiscal 2025, Securities RPM has been volatile, fixed compensation and other expenses are rising, and bad debts increased in the latest quarter.
How Zacks Signals Could Guide an SNEX Decision
Zacks data support the earnings-momentum case, but they do not remove valuation risk. The Zacks Consensus Estimate points to earnings of $6.00 per share for fiscal 2026 and $6.25 for fiscal 2027, up from $3.93 in fiscal 2025. SNEX has also beaten the Zacks Consensus Estimate in two of the trailing four quarters.
Image Source: Zacks Investment Research
For investors, that argues for a balanced stance. SNEX still has strong business momentum, above-industry ROE and credible acquisition benefits. Yet after a major rally and a richer valuation, the stock looks better suited for investors comfortable with execution risk than for those seeking a low-risk entry point.
At present, StoneX sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.